1603 related articles for article (PubMed ID: 17561135)
21. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
Karakiewicz PI; Shariat SF; Palapattu GS; Gilad AE; Lotan Y; Rogers CG; Vazina A; Gupta A; Bastian PJ; Perrotte P; Sagalowsky AI; Schoenberg M; Lerner SP
J Urol; 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant and adjuvant chemotherapy for invasive bladder cancer.
Smith MR; Kantoff PW
Semin Oncol; 1995 Dec; 22(6):625-32. PubMed ID: 8539637
[TBL] [Abstract][Full Text] [Related]
23. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer.
Porter MP; Kerrigan MC; Donato BM; Ramsey SD
Urol Oncol; 2011; 29(3):252-8. PubMed ID: 19450992
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review.
Pectasides D; Pectasides M; Nikolaou M
Eur Urol; 2005 Jul; 48(1):60-7; discussion 67-8. PubMed ID: 15967253
[TBL] [Abstract][Full Text] [Related]
25. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
26. Results with radical cystectomy for treating bladder cancer: a 'reference standard' for high-grade, invasive bladder cancer.
Stein JP; Skinner DG
BJU Int; 2003 Jul; 92(1):12-7. PubMed ID: 12823375
[No Abstract] [Full Text] [Related]
27. [Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group].
Uchida K; Takeshima H; Kikuchi K; Shimazui T; Miyanaga N; Kawai K; Akaza H; Tsuchiya A; Noguchi R; Hattori K; Manabe F; Matsuki K; Suzuki R; Ishikawa S; Kondo F; Kobayashi T; Koiso K
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1179-87. PubMed ID: 9679581
[TBL] [Abstract][Full Text] [Related]
28. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.
Milowsky MI; Stadler WM; Bajorin DF
BJU Int; 2008 Nov; 102(9 Pt B):1339-44. PubMed ID: 19035902
[TBL] [Abstract][Full Text] [Related]
29. De novo muscle invasive bladder cancer: is there a change in trend?
Vaidya A; Soloway MS; Hawke C; Tiguert R; Civantos F
J Urol; 2001 Jan; 165(1):47-50; discussion 50. PubMed ID: 11125361
[TBL] [Abstract][Full Text] [Related]
30. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience.
Choong NW; Quevedo JF; Kaur JS
Cancer; 2005 Mar; 103(6):1172-8. PubMed ID: 15700264
[TBL] [Abstract][Full Text] [Related]
31. Comparison of two-port and four-port irradiation in the bladder preservation therapy for locally invasive bladder cancer.
Sawada Y; Takeuchi Y; Iwasawa T; Kuroda K; Matsushima M; Nagamoto M; Wakayama M
Int J Urol; 2006 Dec; 13(12):1470-4. PubMed ID: 17118019
[TBL] [Abstract][Full Text] [Related]
32. [Neoadjuvant chemotherapy of invasive bladder cancer].
Rassweiler J
Urologe A; 1994 Nov; 33(6):576-81. PubMed ID: 7817459
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
[TBL] [Abstract][Full Text] [Related]
34. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.
Isbarn H; Karakiewicz PI; Shariat SF; Capitanio U; Palapattu GS; Sagalowsky AI; Lotan Y; Schoenberg MP; Amiel GE; Lerner SP; Sonpavde G
J Urol; 2009 Aug; 182(2):459-65; discussion 465. PubMed ID: 19524971
[TBL] [Abstract][Full Text] [Related]
35. Organ preservation for muscle-invasive bladder cancer by transurethral resection.
Leibovici D; Kassouf W; Pisters LL; Pettaway CA; Wu X; Dinney CP; Grossman HB
Urology; 2007 Sep; 70(3):473-6. PubMed ID: 17905099
[TBL] [Abstract][Full Text] [Related]
36. [Adjuvant chemotherapy following total cystectomy for invasive bladder cancer with bleomycin, vincristine and methotrexate].
Takeuchi S; Yamada T; Sekine H; Katoh M; Washizuka M; Fukui I; Yokokawa M
Hinyokika Kiyo; 1984 Nov; 30(11):1619-25. PubMed ID: 6084949
[TBL] [Abstract][Full Text] [Related]
37. Bladder preservation: optimizing radiotherapy and integrated treatment strategies.
Mak RH; Zietman AL; Heney NM; Kaufman DS; Shipley WU
BJU Int; 2008 Nov; 102(9 Pt B):1345-53. PubMed ID: 19035903
[TBL] [Abstract][Full Text] [Related]
38. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
Lambert EH; Pierorazio PM; Olsson CA; Benson MC; McKiernan JM; Poon S
BJU Int; 2007 Jul; 100(1):33-6. PubMed ID: 17552951
[TBL] [Abstract][Full Text] [Related]
39. Transitional cell carcinoma of the bladder in young adults: presentation, natural history and outcome.
Yossepowitch O; Dalbagni G
J Urol; 2002 Jul; 168(1):61-6. PubMed ID: 12050493
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant chemotherapy for bladder cancer. Standard of care or unproven therapy?
Bahnson RR; Smith D; Trump D
Surg Oncol Clin N Am; 1995 Apr; 4(2):287. PubMed ID: 7796287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
